[go: up one dir, main page]

WO2003039553B1 - Compositions pour le traitement de la dysfonction sexuelle feminine postmenopausique - Google Patents

Compositions pour le traitement de la dysfonction sexuelle feminine postmenopausique

Info

Publication number
WO2003039553B1
WO2003039553B1 PCT/US2002/036167 US0236167W WO03039553B1 WO 2003039553 B1 WO2003039553 B1 WO 2003039553B1 US 0236167 W US0236167 W US 0236167W WO 03039553 B1 WO03039553 B1 WO 03039553B1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
estrogen
group
antimuscarinic
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/036167
Other languages
English (en)
Other versions
WO2003039553A1 (fr
Inventor
Chris R Bilkey
Greg J Slatter
Ebrahim Versi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to EP02789581A priority Critical patent/EP1443939A1/fr
Priority to MXPA04004364A priority patent/MXPA04004364A/es
Priority to CA002464707A priority patent/CA2464707A1/fr
Priority to JP2003541844A priority patent/JP2005514345A/ja
Publication of WO2003039553A1 publication Critical patent/WO2003039553A1/fr
Anticipated expiration legal-status Critical
Publication of WO2003039553B1 publication Critical patent/WO2003039553B1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un ensemble de formes posologiques qui comprennent chacune au moins deux agents thérapeutiques choisis dans le groupe constitué (a) d'un oestrogène, (b) d'un androgène et (c) d'un antimuscarinique, dans des dosages total et relatif efficaces sur le plan thérapeutique, pour le traitement de la dysfonction sexuelle féminine ou de l'évitement sexuel postménopausique, ces formes posologiques étant conçues pour une administration intravaginale. L'invention concerne également une méthode de traitement de la dysfonction sexuelle féminine ou de l'évitement sexuel postménopausique qui consiste à administrer par voie intravaginale, selon un schéma de traitement portant sur une période d'au moins 7 jours, des formes posologiques dont au moins une partie comprend au moins deux agents thérapeutiques choisis dans le groupe constitué (a) d'un oestrogène, (b) d'un androgène et (c) d'un antimuscarinique, dans des dosages total et relatif qui sont efficaces sur le plan thérapeutique pour le traitement de la dysfonction sexuelle féminine ou de l'évitement sexuel postménopausique, sans que plus d'une forme posologique ne soit administrée par jour. L'invention concerne également une trousse convenant pour la mise en oeuvre de ce schéma de traitement.
PCT/US2002/036167 2001-11-09 2002-11-12 Compositions pour le traitement de la dysfonction sexuelle feminine postmenopausique Ceased WO2003039553A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02789581A EP1443939A1 (fr) 2001-11-09 2002-11-12 Compositions pour le traitement de la dysfonction sexuelle feminine postmenopausique
MXPA04004364A MXPA04004364A (es) 2001-11-09 2002-11-12 Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica.
CA002464707A CA2464707A1 (fr) 2001-11-09 2002-11-12 Compositions pour le traitement de la dysfonction sexuelle postmenopausique
JP2003541844A JP2005514345A (ja) 2001-11-09 2002-11-12 更年期以降の女性生殖機能障害の治療のための組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34450701P 2001-11-09 2001-11-09
US60/344,507 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003039553A1 WO2003039553A1 (fr) 2003-05-15
WO2003039553B1 true WO2003039553B1 (fr) 2004-07-08

Family

ID=23350815

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/SE2002/002041 Ceased WO2003039524A1 (fr) 2001-11-09 2002-11-07 Agent anti-muscarinique et agoniste des oestrogenes pour traiter une vessie instable ou hyperactive
PCT/US2002/036167 Ceased WO2003039553A1 (fr) 2001-11-09 2002-11-12 Compositions pour le traitement de la dysfonction sexuelle feminine postmenopausique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/SE2002/002041 Ceased WO2003039524A1 (fr) 2001-11-09 2002-11-07 Agent anti-muscarinique et agoniste des oestrogenes pour traiter une vessie instable ou hyperactive

Country Status (6)

Country Link
US (2) US20030118633A1 (fr)
EP (2) EP1441707A1 (fr)
JP (2) JP2005512995A (fr)
CA (2) CA2466336A1 (fr)
MX (2) MXPA04003866A (fr)
WO (2) WO2003039524A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455697A4 (fr) 2001-12-20 2009-08-05 Femmepharma Holding Co Inc Administration de medicaments par voie vaginale
WO2004043429A1 (fr) * 2002-11-12 2004-05-27 Pharmacia & Upjohn Company Therapie combinee pour traiter les dysfonctionnements d'ordre sexuel chez la femme apres la menopause, comprenant un agent androgene, un oestrogene et une agent antimuscarinique
MXPA05007266A (es) 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
WO2006127057A1 (fr) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Administration vaginale non systématique d'oestrogène et androgène pour le traitement de dysfonctionnement sexuel
PL1909973T3 (pl) 2005-07-15 2019-01-31 Micell Technologies, Inc. Polimerowe powłoki zawierające proszek leku o kontrolowanej morfologii
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
WO2007076144A2 (fr) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Compositions d'œstrogènes conjugués, applicateurs, kits et procédés pour les préparer et les utiliser
EP2029128B1 (fr) 2006-05-22 2015-08-05 Hormos Medical Ltd. Procédé de traitement d'une prostatite chronique non bactérienne par des modulateurs sélectifs des récepteurs des strogènes ou par des inhibiteurs de l'aromatase
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
WO2008094877A2 (fr) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions pour l'administration orale de produits pharmaceutiques
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
JP2011518783A (ja) * 2008-04-09 2011-06-30 コンサート ファーマシューティカルズ インコーポレイテッド ３−（２−ヒドロキシ−５−メチルフェニル）−ｎ，ｎ−ジイソプロピル−３−フェニルプロピルアミンの誘導体およびその使用方法
EP2271294B1 (fr) 2008-04-17 2018-03-28 Micell Technologies, Inc. Stents à couches bioabsorbables
GR1006406B (el) * 2008-05-06 2009-05-26 Specifar Abee ���������� ������� ��� ������������� ��������� Μικροδισκια παρατεταμενης αποδεσμευσης της τρυγικης τολτεροδινης
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US20130172853A1 (en) 2010-07-16 2013-07-04 Micell Technologies, Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CA2841360A1 (fr) 2011-07-15 2013-01-24 Micell Technologies, Inc. Dispositif medical d'administration de medicament
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
ES2713523T3 (es) * 2012-07-18 2019-05-22 Georges Debled Composición farmacéutica de mesterolona para deficiencias de dihidrotestosterona en la mujer
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
JP6330024B2 (ja) 2013-03-12 2018-05-23 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
WO2014186532A1 (fr) 2013-05-15 2014-11-20 Micell Technologies, Inc. Implants biomedicaux bioabsorbables
AU2014349132A1 (en) * 2013-10-22 2016-04-14 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositons and methods
WO2018093369A1 (fr) * 2016-11-17 2018-05-24 Goren Ofer A Traitement d'un dysfonctionnement sexuel et pour une qualité de vie sexuelle améliorée
JP2024531662A (ja) * 2021-09-10 2024-08-29 スタテラ ファーマ インコーポレイティド 腹圧性尿失禁及び便失禁の治療、軽減及び／又は予防のための成長及び修復促進化合物の局所送達

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US262115A (en) * 1882-08-01 Moeeis pollak
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
CA2259012C (fr) * 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
CA2311755C (fr) * 1998-08-27 2010-03-23 Pharmacia & Upjohn Ab Formulation de tolterodine therapeutique a liberation controlee
HUP0301813A2 (hu) * 1999-06-11 2003-09-29 Watson Pharmaceuticals, Inc. Nem-orális androgén szteroidok
HUP0303624A3 (en) * 2001-03-28 2005-06-28 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad and process for preparation of the compounds

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US9415142B2 (en) 2006-04-26 2016-08-16 Micell Technologies, Inc. Coatings containing multiple drugs
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants

Also Published As

Publication number Publication date
EP1441707A1 (fr) 2004-08-04
MXPA04003866A (es) 2004-07-08
WO2003039524A1 (fr) 2003-05-15
JP2005512995A (ja) 2005-05-12
US20030130244A1 (en) 2003-07-10
WO2003039553A1 (fr) 2003-05-15
JP2005514345A (ja) 2005-05-19
CA2466336A1 (fr) 2003-05-15
CA2464707A1 (fr) 2003-05-09
MXPA04004364A (es) 2004-08-11
US20030118633A1 (en) 2003-06-26
EP1443939A1 (fr) 2004-08-11

Similar Documents

Publication Publication Date Title
WO2003039553B1 (fr) Compositions pour le traitement de la dysfonction sexuelle feminine postmenopausique
CA1329126C (fr) Composes ayant des activites anti-progestatives et anti-oestrogeniques pour le declenchement du travail et pour l'interruption de grossesse, ainsi que pour le traitement de troubles gynecologiques
US5888543A (en) Oral contraceptives
AU710819B2 (en) Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
RU2189819C2 (ru) Схемы приема прогестогена-антипрогестогена
RU2001117204A (ru) Трехфазный пероральный контрацептив
JPH09169649A (ja) 避妊のための多段階調剤
AU726091B2 (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
EP1862167A3 (fr) Méthodes et formulations pour le traitement des dysfonctions sexuelles chez la femme
CN1073422C (zh) 抗孕激素在制备减少子宫出血的药物中的应用
RU99101114A (ru) Схемы приема прогестогена-антипрогестогена
KR960700727A (ko) 호르몬 대체 치료(hormone replacement therapy)
CA2225724A1 (fr) Preparation pharmaceutique combinee, necessaire et methode de contraception orale
US3795734A (en) Cyclic regimen of hormone administration for contraception
KR19990076685A (ko) 게스타겐 및 에스트로겐의 배합을 포함하는 암컷 포유동물용 피임 방법 및 키트
HK1205468A1 (en) Extended estrogen dosing contraceptive regimen
WO2006042021B1 (fr) Procedes de traitement hormonal utilisant des schemas posologiques a cycle etendu a augmentation de dosage
KR20000029537A (ko) 경구피임약
EP0921804B1 (fr) Methode contraceptive orale a deux phases et kit comportant une combinaison d'une progestine et d'un oestrogene
FI83593C (fi) Antikonceptionssammansaettning.
KR890009407A (ko) 폐경기증세 및 골다공증의 치료를 위한 약학적 투여단위
CA2248841A1 (fr) Combinaison sequentielle oestrogene/antagoniste de la progesterone s'utilisant en therapie hormonale de substitution
AU2003206424B2 (en) Sequential estrogen/progesterone antagonist combination for hormone replacement therapy
WO1997041868A1 (fr) Contraceptif oral
Coutinho The vaginal contraceptive pill

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004364

Country of ref document: MX

Ref document number: 2002789581

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003541844

Country of ref document: JP

B Later publication of amended claims

Effective date: 20030523

WWP Wipo information: published in national office

Ref document number: 2002789581

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002789581

Country of ref document: EP